The ability to rapidly identify small molecules that non-covalently bind to a specific target is a critical tool that will benefit many promising therapeutic targets. Affinity selection mass spectrometry (ASMS) has gained significant momentum as a powerful approach for identifying novel compounds that engage with protein and oligonucleotide therapeutic targets. This article breaks down three critical aspects to consider to maximize the success rate of an ASMS-based drug discovery program.
Better. Faster. Label-Free.